Canaccord Genuity Sees Buying Opportunity in Biohaven Pharmaceutical (BHVN)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/18/2026

1. SPY
2. EYPT
3. NVDA
4. AWK
5. TSLA
6. GNK
7. USO
8. ARGX
9. SPCX
10. AZN

Go back to Canaccord Genuity Sees Buying Opportunity in Biohaven Pharmaceutical (BHVN)

Biohaven (BHVN) Prices 6.977M Shares Common Offering at $43/Sh

June 19, 2019 5:53 AM EDT

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinicalstage biopharmaceutical company with a portfolio of innovative, latestage product candidates targeting migraine and neurological diseases, including rare disorders, today announced the pricing of its underwritten public offering of 6,976,745 of its common shares... More

SVB Leerink Sees Biohaven (BHVN) Equity Raise as a Disappointment But Notes a Possible Silver Lining

June 18, 2019 8:52 AM EDT

SVB Leerink analyst Marc Goodman weighed in on Biohaven Pharmaceutical Holding (NYSE: BHVN), noting the $300 million equity raise will be a disappointment to investors.

The analyst notes investors assume the company is raising money to go it alone commercially with its migraine franchise... More

Biohaven (BHVN) Announces Proposed $300M Share Common Offering

June 18, 2019 5:55 AM EDT

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinicalstage biopharmaceutical company with a portfolio of innovative, latestage product candidates targeting neurological diseases, including rare disorders, today announced that it has commenced an underwritten public offering of $300 million of its common... More